Endo Flashcards
HbA1c goal for high risk patients in the ICU
A. <5.6%
B. 7%
C. <8%
D. 9.5%
E. 100-125
C. <8%
Normal HBA1c
A. <5.6%
B. 7%
C. <8%
D. 9.5%
E. 100-125
A. <5.6%
Target weight loss among overweight DM patients
A. <5.6%
B. 7%
C. <8%
D. 9.5%
E. 100-125
B. 7%
Level of glucose of prediabetics
A. <5.6%
B. 7%
C. <8%
D. 9.5%
E. 100-125
E. 100-125
Level of HBA1c that needs insulin injection
A. <5.6%
B. 7%
C. <8%
D. 9.5%
E. 100-125
D. 9.5%
- 3 treatments for hypoglycemia *
A. Soda drink/Dextrose/glucagon
B. Jelly/ hypoglycemic drug/ dextrose
C. Glucagon/ dextrose/ protein bar
D. Soda/ dextrose/ brewed coffee
A. Soda drink/Dextrose/glucagon
- Agents which increase the amount of insulin secreted in pancreas *
A. biguanide
B. sulfonylureas
C. Acarbose
D. Amylin
B. sulfonylureas
Secretagogues:
Sulfonyureas
Meglitides
- Top 3 considerations in Drug therapy *
A. Price, efficacy, place in therapy
B. Hypoglycemia risk, price, efficacy
C. Place in therapy, efficacy, hypoglycemia risk
D. Efficacy, Price, hypoglycemia risk
C. Place in therapy, efficacy, hypoglycemia risk
- Effect of combination of metformin and IV media contrast *
A. Lactic Acidosis
B. Hyperventilation
C. Rebound hyperglycemia
D. Vomiting
A. Lactic Acidosis
- How many generations does Sulfonylureas have? *
A. 1
B. 2
C. 3
D. 4
C. 3
- 3 features of metformin *
A. first line/ gluconeogenesis/ weight loss
B. low cost/ weight loss/ second line
C. gluconeogenesis/ low cost/ weight gain
D. first line/ low cost/ lipolysis
A. first line/ gluconeogenesis/ weight loss
- 2 important indications of Glipizide *
A. liver disease and pediatric population
B. Reproductive age and asthma
C. Renal disease and liver disease
D. Elderly and renal impairment
D. Elderly and renal impairment
- Effect of GLP1 *
A. destroys DPP4 and GIP
B. triggers Beta to release insulin, prevents alpha from releasing glucagon
C. releases glucagon and prevents release of insulin
D. insulin sensitizer
B. triggers Beta to release insulin, prevents alpha from releasing glucagon
- Action of DPP4 Inhibitor*
A. destroys GLP1 and GIP
B. releases glucagon and prevents release of insulin
C. triggers Beta to release insulin, prevents alpha from releasing glucagon
D. insulin secretagogue
C. triggers Beta to release insulin, prevents alpha from releasing glucagon
- Drugs that are effective in decreasing HBA1c *
A. DPP4 inhibitor and SGL2 inhibitor
B. Alpha glucosidase inhibitor and amylin agonist
C. Biguanide and DPP4 inhibitor
D. Biguanide and Sulfonylureas
D. Biguanide and Sulfonylureas
- Can be given to both type 1 and type 2 Diabetes *
A. Acarbose
B. Amylin
C. Exenatide
D. Sitagliptin
B. Amylin
- Drugs that commonly cause flatulence *
A. Acarbose
B. Amylin
C. Exenatide
D. Sitagliptin
A. Acarbose
- Which of the following can cause weight loss *
A. Glyburide
B. Acarbose
C. Pioglitazone
D. Pramlintide
D. Pramlintide
- TRUE about thyrotropin alpha, EXCEPT *
A. used to diagnose cancer recurrence
B. cannot cause cancer
C. used to treat cancer
D. synthetic form of TSH
B. cannot cause cancer
- Patch, was known to have hyperthyroidism for 2 years. One morning he experienced difficulty of
breathing, very strong palpitation, diarrhea, diaphoresis, headache, periorbital edema and high blood
pressure. He was brought to the ER. The following drugs are expected to be given to him, EXCEPT: *
A. RAI
B. PTU
C. Propanolol
D. Diltiazem
A. RAI
Thyroid storm medication:
Propanolol
Diltiazem
Potassium Iodide
Propylthiouracil
Hydrocortisone
- Which of the following can be given to prevent mental retardation in babies with congenital
hypothyroidism? *
A. Liothyronine
B. PTU
C. Levothyroxine
D. Methimazole
C. Levothyroxine
- Preparation of radioactive iodine
A. Sodium iodide 161
B. Sodium iodide 131
C. Potassium iodide 161
D. Potassium iodide 131
B. Sodium iodide 131
- Longer half life
- Better for pregnant women
- Aplasia cutis
- Agranulocytosis
- Inhibit conversion of T4 to T3
A. PTU
B. Methimazole
B. Methimazole
- Longer half life
- Aplasia cutis
A. PTU
- Better for pregnant women
- Inhibit conversion of T4 to T3
- Agranulocytosis
Match the Drug with the target organ *
Biguinides: Metformin
A. Stomach
B. Pancreas
C. Muscle
D. Liver
E. Kidney
F. Intestines
D. Liver
Match the Drug with the target organ *
TZD : Rosiglitazone
A. Stomach
B. Pancreas
C. Muscle
D. Liver
E. Kidney
F. Intestines
C. Muscle
Match the Drug with the target organ *
SGLT2: Canagliflozin
A. Stomach
B. Pancreas
C. Muscle
D. Liver
E. Kidney
F. Intestines
E. Kidney
Match the Drug with the target organ *
GLP-1: Exenatide
DPP-4: -gliptin (Sinagliptin)
alpha-glucosidase: Acarbose
A. Stomach
B. Pancreas
C. Muscle
D. Liver
E. Kidney
F. Intestines
A. Stomach
Match the Drug with the target organ *
Sulfonyureas: Glipizide
Meglitide: Repaglinide
A. Stomach
B. Pancreas
C. Muscle
D. Liver
E. Kidney
F. Intestines
B. Pancreas
For Numbers 84-: Match the drug with the mechanism of interaction with thyroid drugs *
Lithium
Iodine
Amiodarone
A. Reduce hormone production
B. Reduce hormone absorption
C. Increase metabolism
D. displace hormone
A. Reduce (thyroid) hormone production
For Numbers 84-: Match the drug with the mechanism of interaction with thyroid drugs *
Sucralfate
FeSO4
Cholestyramine
Colestipol
Aluminum (Antacids)
A. Reduce hormone production
B. Reduce hormone absorption
C. Increase metabolism
D. displace hormone
B. Reduce (Thyroid) hormone absorption
For Numbers 84-: Match the drug with the mechanism of interaction with thyroid drugs *
Rifampin
Phenobarbital
Carbamazepin
Warfarin
Oral Hypogycemic
A. Reduce hormone production
B. Reduce hormone absorption
C. Increase metabolism
D. displace hormone
C. Increase metabolism (of thyroxine)
For Numbers 84-: Match the drug with the mechanism of interaction with thyroid drugs *
Furosemide
Mefanamic Acid
Salicylates
A. Reduce hormone production
B. Reduce hormone absorption
C. Increase metabolism
D. displace hormone
D. displace hormone (thyroid hormone from protein binding)`
For Numbers 91- : Rank the following agents based on their potency (ability to reduce HbA1C).
1 being the
first line of treatment.
- Amylin agonists
- SGTLT2 inhibitors
- Meglitinides
- Biguanides
- DPP4 inhibitor
1- Biguanides
Meglitinides
Amylin
DPP4
SGLT2
BSMT
AGADS
Amylin
GLP-1
A-glucosidase
DPP4
SGLT2
- True about inhaled rapid actin insulin
A. effect is prandial
B. onset of action is 90 mins
C. effects are prandial and basal
D. onset of action is 6 hours
A. effect is prandial
- Intermediate Acting:
Insulin NPH
A. taken before meals, onset at 10-30 mins after injection
B. taken before meals, onset at 30-60 mins after injection
C. taken with or without meals, peak at 4-12 hours
D. taken with or without meals, without peaks.
C. taken with or without meals, peak at 4-12 hours
- Long Acting:
Insulin Glargine/Detemir
A. taken before meals, onset at 10-30 mins after injection
B. taken before meals, onset at 30-60 mins after injection
C. taken with or without meals, peak at 4-12 hours
D. taken with or without meals, without peaks.
D. taken with or without meals, without peaks.
- Short Acting:
Insulin Regular Human
A. taken before meals, onset at 10-30 mins after injection
B. taken before meals, onset at 30-60 mins after injection
C. taken with or without meals, peak at 4-12 hours
D. taken with or without meals, without peaks.
B. taken before meals, onset at 30-60 mins after injection
- Rapid- Acting:
Insulin Lispro/ Aspart/ Glulisine
A. taken before meals, onset at 10-30 mins after injection
B. taken before meals, onset at 30-60 mins after injection
C. taken with or without meals, peak at 4-12 hours
D. taken with or without meals, without peaks.
A. taken before meals, onset at 10-30 mins after injection